Skip to content

NeoGenomics NEO Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
Personalis, Inc. logo
Personalis, Inc.PSNL
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
GeneDx Holdings logo
GeneDx HoldingsWGS

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's operating lease right-of-use assets in other assets?
NeoGenomics (NEO) reported operating lease right-of-use assets in other assets of $76.7M in Q1 2026.
How has NeoGenomics's operating lease right-of-use assets in other assets changed year-over-year?
NeoGenomics's operating lease right-of-use assets in other assets decreased by 1.4% year-over-year, from $77.8M to $76.7M.
What is the long-term trend for NeoGenomics's operating lease right-of-use assets in other assets?
Over 5 years (2020 to 2025), NeoGenomics's operating lease right-of-use assets in other assets has grown at a 11.4% compound annual growth rate (CAGR), from $45.79M to $78.44M.